AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1
slide-2
slide-3

Hervycta 150 + Injection

Prescription Icon
Prescription Required

Marketer

Dr Reddy's Laboratories Ltd

Salt Composition

Trastuzumab (150mg)

Overview Hervycta 150 + Injection

Trastuzumab injection (Hervycta 150+) is indicated for breast and gastric cancers. Its mechanism involves targeting and destroying cancerous cells by suppressing HER2 protein activity. Administration is strictly by injection from a qualified healthcare provider. Dosage and frequency are determined by your physician based on your condition and may vary. Adhere precisely to your doctor's prescribed regimen; incorrect usage or overdose risks severe adverse reactions. Therapeutic effects may not be immediately apparent, potentially requiring weeks or months; discontinue only under medical supervision. Frequent side effects include nausea, headache, skin rash, sleep disturbances, and infections. This medication can lower blood cell counts (red and white), raising infection risk. Regular blood tests to monitor blood cell levels, cardiac function, liver health, and uric acid are mandatory. Report shortness of breath, cough, chills, or limb swelling to your doctor immediately. Inform your healthcare team of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and lactation. Reliable contraception for both partners is crucial throughout treatment to prevent conception.

Primary Ingredients of Hervycta 150 + Injection

The provided text is "undefined," therefore no rephrasing is possible.

Uses of Hervycta 150 + Injection

Cancers affecting the breast and stomach.

Major Benefits of Hervycta 150 + Injection:

This medication will be administered by your healthcare provider; self-medication is strongly discouraged.

Common Side effects of Hervycta 150 + Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Hervycta 150 + Injection:

This medication will be administered by your healthcare provider; self-medication is strictly prohibited.

How Hervycta 150 + Injection works:

Hervycta 150 + Injection is a monoclonal antibody engineered from IgG1. This therapy targets HER2, a human epidermal growth factor receptor protein, whose overexpression drives unchecked growth in breast and gastric cancers. By binding to HER2, it neutralizes the receptor's activity and disrupts several downstream signaling cascades vital for cancer progression, leading to cancer cell death.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent use of Hervycta 150 + Injection and alcohol can lead to increased sleepiness.

PregnancyPregnancyCONSULT YOUR DOCTOR

Using Hervycta 150 + Injection during pregnancy poses a confirmed risk to the fetus. Its use should be avoided except in critical circumstances where the potential benefits significantly outweigh the known hazards, as determined by a physician. Always seek medical advice before use.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administration of Hervycta 150 + Injection while breastfeeding is likely inadvisable. Preliminary human evidence indicates potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

Hervycta 150 + Injection's impact on driving ability is undetermined. Refrain from driving if you experience symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

The use of Hervycta 150 + Injection in individuals with kidney impairment is likely safe. Existing evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.

LiverLiverCONSULT YOUR DOCTOR

Data regarding Hervycta 150 + Injection use in individuals with hepatic impairment is scarce. Physician consultation is recommended.

What if you forget to take Hervycta 150 + Injection :

Should you inadvertently omit a dose of Hervycta 150 + Injection, seek medical advice.

Facts to Know About Hervycta 150 + Injection

LabelValue
Chemical Type Monoclonal antibody
Developing Habits No.
Treatment Category Cancer Medications
Actions Monoclonal Antibody HER2/neu (ErbB2) Inhibitor

FAQs on Hervycta 150 + Injection

Hervycta 150+ Injection may cause side effects including sore throat, fever, chills, fatigue, pale skin, nosebleeds, unusual bruising or bleeding, stomach pain, seizures, hallucinations, muscle cramps, spasms, nausea, vomiting, loss of appetite, rapid heartbeat, discolored or decreased urine output, painful urination, and other signs of infection. Contact your doctor immediately if you experience any of these symptoms.
Effective contraception must be used by women of childbearing age throughout Hervycta 150 + Injection therapy and for seven months afterward. Pregnancy planning can resume seven months post-treatment.
Treatment with Hervycta 150 + Injection for patients with early-stage breast cancer should continue for one year or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Hervycta 150 + Injection does not require fasting beforehand. Administration must be supervised by a qualified oncologist and performed only by a healthcare professional.
Hervycta 150 + Injection is available in two formulations: intravenous infusion and subcutaneous injection. Always verify the correct formulation is administered as prescribed, checking the product label. The intravenous formulation is for intravenous infusion only; it must not be given subcutaneously. Your doctor may change your treatment between intravenous and subcutaneous Hervycta 150 + Injection as clinically appropriate.
Hervycta 150 + Injection is a monoclonal antibody targeting the HER2 protein, abundant on the surface of some cancer cells. Its mechanism of action involves binding to HER2, inhibiting cancer growth and spread. Consequently, it's only effective in HER2-positive cancers and is contraindicated in HER2-negative cases.
Using Hervycta 150 + Injection with anthracyclines (like doxorubicin) can harm your heart. Your doctor must assess your heart health before and during treatment.
Cardiac evaluations are necessary at treatment initiation, every three months during treatment, and every six months post-treatment for up to 24 months following the final Hervycta 150 + Injection dose. Patients with pre-existing cardiac conditions require evaluations every twelve weeks.
Hervycta 150 + Injection
16,662
MRP 20,300
17% off